Valuation: Castle Biosciences, Inc.

Market Cap 915M 790M 743M 676M 1.27B 87.53B 1.29B 8.72B 3.41B 43.84B 3.44B 3.36B 146B P/E 2026 *
-22.8x
P/E 2027 * -29.3x
Enterprise Value 915M 790M 743M 676M 1.27B 87.53B 1.29B 8.72B 3.41B 43.84B 3.44B 3.36B 146B EV / Sales 2026 *
2.45x
EV / Sales 2027 * 2.23x
Free-Float
97.44%
Yield 2026 *
-
Yield 2027 * -
1 day-3.07%
1 week-10.26%
Current month+3.68%
1 month+20.16%
3 months+51.75%
6 months-13.14%
Current year-25.37%
1 week 28.72
Extreme 28.72
33
1 month 23.25
Extreme 23.25
33.06
Current year 17.72
Extreme 17.722
44.28
1 year 17.72
Extreme 17.722
44.28
3 years 12.07
Extreme 12.07
44.28
5 years 9.26
Extreme 9.2601
78.58
10 years 9.26
Extreme 9.2601
107.69
Manager TitleAgeSince
Chief Executive Officer 64 2007-08-31
Director of Finance/CFO 56 2017-11-30
Chief Tech/Sci/R&D Officer - 2021-11-30
Director TitleAgeSince
Director/Board Member 64 2007-08-31
Chairman 64 2014-08-31
Director/Board Member 70 2018-12-05
Date Insider Type Main position Quantity % Market Cap.
8/5/26 Fiscal year

Founder

8,667 0.0286%
8/3/26 Sell

Chief Operating Officer

-8,586 0.0283%
8/3/26 Sell

Executive/Senior Manager

-1,730 0.0057%
Change 5-day change 1-year change 3-year change Capi.($)
-3.07%-10.26%+44.50%+68.19% 915M
-0.96%-4.24%+171.94%+350.41% 21.7B
+0.41%-0.55%-42.10%-20.47% 9.9B
-4.07%-5.02%+316.39%+20.39% 7.56B
-0.64%-0.71%+85.05%+52.23% 6.59B
-3.05%-10.38%-42.55% - 6.11B
+3.89%+9.04%-9.18%-3.26% 6B
-1.73%+2.81%+83.84%+112.31% 4.7B
-1.05%-3.36%-12.28%-17.37% 4.27B
+4.53%+4.60%-17.46%-30.47% 2.79B
Average -0.02%-0.14%+57.82%+59.11% 7.05B
Weighted average by Cap. +0.29%-0.70%+89.10%+129.02%

Financials

2026 *2027 *
Net sales 373M 322M 303M 276M 518M 35.68B 526M 3.55B 1.39B 17.87B 1.4B 1.37B 59.51B 409M 354M 333M 303M 569M 39.17B 578M 3.9B 1.53B 19.62B 1.54B 1.5B 65.34B
Net income -38.03M -32.86M -30.89M -28.1M -52.84M -3.64B -53.69M -362M -142M -1.82B -143M -140M -6.07B -27.75M -23.97M -22.54M -20.51M -38.56M -2.66B -39.17M -264M -104M -1.33B -104M -102M -4.43B
Net Debt - -
Logo Castle Biosciences, Inc.
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
Employees
1,002
Date Price Change Volume
26-08-18 US$29.00 -3.17% 596,609
26-08-17 US$29.95 +1.11% 225,807
26-08-14 US$29.62 -3.04% 264,212
26-08-13 US$30.55 -2.80% 362,229
26-08-12 US$31.43 -2.51% 435,995
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
29.00USD
Average target price
44.00USD
Spread / Average Target
+51.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CSTL Stock